Trial Profile

A Multinational Prospective Psoriatic Arthritis Observational Study of Persistence of Treatment (Pro-Spirit)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ixekizumab (Primary) ; Mirikizumab (Primary) ; Secukinumab (Primary) ; Interleukin-12; Janus kinase inhibitors; Tumour necrosis factor inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
Indications Psoriatic arthritis
Focus Therapeutic Use
Acronyms Pro-Spirit

Most Recent Events

15 Jun 2024 Results investigating the RW use of biological or targeted-synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in PsA, presented at the 25th Annual Congress of the European League Against Rheumatism
10 Jul 2023 New trial record
03 Jun 2023 Design and Full Baseline Sample Characteristics of Patients (n=1207 ), presented at the 24th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com